from Reuters: Health News https://reut.rs/2Elmjud
Friday, March 1, 2019
ImmunoGen drug fails cancer study, shares slide 40 percent
U.S. drug developer ImmunoGen Inc said on Friday its experimental ovarian cancer drug failed to meet the main goal of a late-stage study, driving its shares more than 40 percent lower on Friday.
from Reuters: Health News https://reut.rs/2Elmjud
from Reuters: Health News https://reut.rs/2Elmjud
Subscribe to:
Post Comments (Atom)
-
(Reuters Health) - More than half of heart failure patients who visit the emergency room don't receive prompt follow-up care, and a Cana...
-
WEIGHT LOSS supplements could help overweight or obese patients with the diet plans. You could lose weight and avoid weight gain by adding...
-
A U.S. appeals court on Wednesday declined a request by Johnson & Johnson for an temporary restraining order blocking sales of generic v...
No comments:
Post a Comment